For Bristol, Plavix Ruling Bodes Well In Patent Trial
This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.
Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY) now have the upper hand in an upcoming patent trial over their blockbuster heart drug Plavix, if Thursday’s court injunction in the case is any indication.
The main reason: In granting an injunction halting sales of a generic version of Plavix, U.S. Judge Sidney Stein in New York concluded that Bristol-Myers and Sanofi-Aventis were likely to prevail over generic marketer Apotex Inc. at a trial scheduled to begin in January. Stein is the judge who will deliver the verdict in the non-jury trial.
A login link has been sent to
Enter your email to read this article.
Get 2 free articles when you subscribe.
